Cancer Communications. 2024;44:287-293.



CANCER

Identification of telomere maintenance gene variations related to lung adenocarcinoma risk by genome-wide association and whole genome sequencing analyses

Dear editor,

Lung carcinoma is responsible for the highest fatality rate among cancer-related deaths globally, with lung adenocarcinoma (LADC) emerging as the prevailing subtype. LADC is characterized by two distinctive attributes in individuals of Asian ancestry: firstly, Asian patients with LADC are more frequently non-smokers (approximately 40%) than their European counterparts (around 10%) [1]; secondly, approximately 50% of Asian LADC patients have oncogenic mutations in the epidermal growth factor receptor (EGFR) gene, whereas this frequency is around 10% in European and American patients [2]. Hence, it is plausible that risk factors exerting a more pronounced influence in Asian than in European/American populations contribute to LADC pathogenesis, irrespective of smoking status. To date, over 50 genomic loci associated with heightened susceptibility to lung carcinoma have been unearthed through genome-wide association studies (GWAS) investigating single nucleotide polymorphisms (SNPs) in East Asian and European/American patients [2–5]. A subset of these loci, including 5p15 (telomerase reverse transcriptase, TERT) and 3q28 (tumor protein p63, TP63), are associated with LADC risk in both populations. Hence, despite genetic disparities between Caucasian and Asian populations, the

List of abbreviations: GWAS, genome-wide association studies; LADC, lung adenocarcinoma; WGS, whole genome sequencing; SNP, single nucleotide polymorphism; EGFR, epidermal growth factor receptor; TERT, telomerase reverse transcriptase; TP63, tumor protein p63; TERC, telomerase RNA component; POT1, protection of telomeres 1; PTPRG, protein tyrosine phosphatase receptor type G; BTN2A1, butyrophilin subfamily 2 member A1; HLA-C, major histocompatibility complex, class I, C; HLA-DQB1, major histocompatibility complex, class II, DQ beta 1; BAK1, BCL2 antagonist/killer 1; ASB15, ankyrin repeat and SOCS box containing 15; SECISBP2L, SECIS binding protein 2 like; TERF1, telomeric repeat binding factor 1; TINF2, TERF1 interacting nuclear factor 2; OBFC1, OB-fold-containing 1; TRF1, telomeric repeat binding factor 1; RAP1, TERF2 interacting protein; LTL, leukocyte telomere length. populations share genetic factors contributing to lung carcinoma susceptibility.

We performed a meta-analysis encompassing two novel GWAS, comprising 5,416 individuals diagnosed with LADC and 29,696 control subjects (Supplementary Tables S1-S2, Supplementary Figure S1). Additionally, we compared susceptibility loci identified in European ancestry populations with our GWAS data. Five variants were associated with LADC risk in both our GWAS ($P < 5.0 \times$ 10^{-6}) and a previous GWAS meta-analysis [3] (Supplementary Table S3). We also compared our findings with top associated SNPs from the latest GWAS [5] (Supplementary Table S4). Subsequently, the most strongly associated SNPs on conditional analysis in non-major histocompatibility complex (HLA) (Supplementary Table S5, Supplementary Figure S2) and HLA regions (Supplementary Table S6, Supplementary Figure S3) were validated in an independent dataset comprising 11,670 patients with LADC and 121,958 controls (Supplementary Figure S4). We detected significant associations of 19 genomic loci and LADC risk, characterized by highly significant P values (6.9 \times 10^{-11} to 4.8×10^{-134}). Notably, four of these loci harbor three genes, telomerase RNA component (TERC), TERT, and protection of telomeres 1 (POT1), involved in regulating telomere maintenance (Supplementary Table S7). Associations with 10 loci previously reported in Asian populations (including two loci in TERT) [2, 4] and two loci reported in a Caucasian population [3] were validated in the present study (Supplementary Table S7). Additionally, we identified seven novel associated loci: protein tyrosine phosphatase receptor type G (PTPRG), TERC, butyrophilin subfamily 2 member A1 (BTN2A1), major histocompatibility complex, class I, C (HLA-C), major histocompatibility complex, class II, DQ beta 1 (HLA-DQB1), BCL2 antagonist/killer 1 (BAK1), and ankyrin repeat and SOCS box containing 15 (ASB15) (Supplementary Table S7).

We also inferred the biological effects of other LADC risk-associated SNP-containing loci identified in the

287

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.




FIGURE 1 Association of novel susceptibility loci with risk for lung adenocarcinoma according to *EGFR* mutation types and association between genotype and leukocyte telomere length. (A) A Forest plot showing associations between 19 SNPs and the presence or absence of *EGFR* mutations. Odds ratios were adjusted for age, sex, smoking status (never vs. ever smoking), and the top five principal components. Combined meta-analysis was performed using a fixed-effects model. *P*-values of SNPs that differed significantly between patients with LADC with and without *EGFR* mutations in case-case analysis are shown. (B) Association between *TERC, TERT*, and *POT1* genotypes and LTL. (C) Association between LADC risk and LTL in 19 LADC risk-associated SNPs. (D) Association between SNPs in telomere maintenance genes and LTL in our cohort (X-axis) and in GWAS catalog data (Y-axis).

Abbreviations: *EGFR*, epithelial growth factor receptor; Ctrl, control; KGP p3, 1000 genomes project phase 3; RSQR, imputation quality; LADC, lung adenocarcinoma; LTL, leukocyte telomere length; *TERC*, telomerase RNA component; *TERT*, telomerase reverse transcriptase; *POT1*, protection of telomeres 1; TL, telomere length; SNP, single nucleotide polymorphism; *TINF2*, TERF1 interacting nuclear factor 2; *OBFC1*, OB-fold-containing 1.

present study through differential expression analysis in normal lung or blood cells: SECIS-binding protein 2-like (*SECISBP2L*; which encodes a putative tumor suppressor protein substrate of Aurora-A kinase), *BAK1* (encoding a pro-apoptotic BCL2 family protein), and *BTN2A1* (encoding a butyrophilin-like protein involved in regulation of $\gamma\delta$ T-cell development and differentiation) (Supplementary Figure S5). Our data indicate that the identified risk-associated loci likely exert an impact on LADC development and immune evasion. Furthermore, we assessed the relationship between the 19 significantly associated SNPs and LADC risk based on somatic *EGFR* mutations in tumor cells (Figure 1A and Supplementary Table S8). Intriguingly, 15 of the 19 SNPs had higher odds ratios in patients with *EGFR*-mutated tumors than in those without such mutations (Supplementary Table S9). Notably, the differences in association according to somatic *EGFR* mutations attained statistical significance for *TERT* and HLA-class II SNPs, reinforcing findings from our previous small-scale GWAS [2]; however, further validation studies are needed to more accurately assess the associations of these SNPs with risk of LADC with *EGFR* mutations.

The associations between SNPs in three genes responsible for telomere maintenance (TERT, TERC, and POT1) and risk of LADC prompted us to explore how these genetic variations influence telomere biology. To accomplish this, we conducted whole-genome sequencing (WGS) of tumor and non-tumor DNA samples obtained from 964 patients with LADC (Supplementary Table S10). Consistent with previous investigations [6], we found that women had longer leukocyte telomere lengths (LTLs) than men, and that LTLs decreased with advancing age, thereby validating the accuracy of our LTL estimation method (Supplementary Figure S6). Notably, the presence of TERT and TERC risk variants tended to be indicative of elevated LTL (P < 0.01) regardless of sex (Figure 1B, Supplementary Figure S7, Supplementary Table S11). Further, variants in the TERT, TERC, and POT1 genes were nominally associated with LADC risk and longer LTL (P < 0.01) (Figure 1C). Furthermore, we investigated the associations between 398 variants previously linked to both LADC risk and LTL (compiled from the GWAS catalog, https://www.ebi.ac.uk/gwas/) with LTL in our cohort. Intriguingly, we observed that four risk variants in three additional genes involved in telomere maintenance, namely, telomeric repeat-binding factor 1 (TERF1), TERF1-interacting nuclear factor 2 (TINF2), and OBfold-containing 1 (OBFC1), exhibited a tendency toward association with longer LTLs (P < 0.01) (Figure 1D, Supplementary Table S12) and LADC risk. Further validation studies are needed. Physiologically, LTL is tightly governed by telomerase enzymes, including TERC, TERT, and OBFC1, along with shelterin proteins, such as telomeric repeat-binding factor 1 (TRF1), TERF2-interacting protein (RAP1), TERF1, and POT1, which bind to specific DNA sequences at chromosome termini [6]. The current discovery aligns harmoniously with a recent study indicating that hereditary POT1 mutations were associated with extended telomere length and conferred a predisposition to a familial clonal hematopoiesis syndrome accompanied by development of various solid tumors [7]. A recent Mendelian randomization analysis study established a positive association between longer telomere length and an elevated risk of developing LADC [8]. Building on this discovery, our findings shed further light by demonstrating that common variants within telomere maintenance genes contribute to telomere elongation and increase susceptibility to LADC in Asian populations. Intriguingly, these variants exhibited associations with LTL, while demonstrating no association with telomere length, structural variant count, or tumor mutational burden in 642 patients with LADC (Supplementary Figure S8, Supplementary Table S13). These findings imply that genetic polymorphisms in telomere maintenance genes facilitate telomere elon289

Here, we conducted an extensive GWAS, leading to the identification of 19 susceptibility loci associated with LADC. By WGS analysis of 964 samples from patients with LADC, we discovered that risk alleles within the TERT and TERC genes were linked to elongated telomeres in non-tumor cells, while having no impact on telomere length, mutation status, or structural characteristics of tumor cells. These findings indicate that the presence of long telomeres, conferred by genetic polymorphisms in individuals of Asian descent, fosters the survival of lung epithelial cells and heightens their propensity to undergo malignant transformation. Further elucidation of the distinct and cumulative effects of the 19 LADC risk-associated loci will significantly augment our comprehension of this disease, thereby advancing endeavors toward its treatment and prevention.

DECLARATIONS

AUTHOR CONTRIBUTIONS

Ko.S. and Ta.K. undertook conceptualization. GWAS was performed by Ko.S.; A.T.; Yu.M.; Y.D.; T.Ka.; M.K.; H.I.; F.M.; Y.K.; and Ke.M. Clinical and/or genetic information on study subjects was collected by H.K.; S.M.; H.H; A.G.; Ta.H.; Ki.S.; M.Sa.; Yu.O.; S.W.; K.G.; M.T.; Kat.T.; Ma.K.; Yoh.M.; Ka.T.; Hi.S.; D.M.; Tak.Y.; Ta.M.; Tai.Y.; Y.G.; Ta.Yo.; Ta.Ya.; M.So.; S.To.; K.Y.; Ka.M.; F.T.; M.H.; N.F.; S.S.N.; N.M.; T.S.; Y.N.; K.Ku.; K.Tak.; K.Tan.; Y.Y.; Ku.S.; T.H.; T.M.; Ha.N.; T.N.; Y.O.; N.S.; Y.M.; K.Ku.; K.Take.; Ko.T.; Y.Y.; Ku.S.; T.H.; Tai.M.; H.N.; T.Y.; T.N.; Y.O.; K.Im.; Yo.M.; K.O.; Ka.I.; K.W.; A.S.; M.Y.; M.I.; Ko.M.; J.I.; and Y.M. Omics analysis was undertaken by Ko.S.; S.K.; D.T.; A.S.; S.Ta.; T.A.; A.T.; M.M.; Y.S.; H.S.; T.Y.; M.A.; H.T.; K.Im.; K.Taka.; K.Ko.; H.N.; R.H.; and Y.K. All authors reviewed the manuscript draft and revised it critically for intellectual content. All authors approved the final version of the manuscript to be published.

ACKNOWLEDGMENTS

We thank all of the subjects for participating in the study, as well as the collaborating physicians for assisting with sample collection. We are grateful to the National Cancer Center Biobank, BioBank Japan, Tohoku Medical Megabank Organization (ToMMo), Iwate Tohoku Medical Megabank Organization (Iwate Medical University), the Japan Public Health Center (JPHC)-based Prospective Study, the Japan Multi-Institutional Collaborative Cohort (J-MICC) Study, and Kanagawa Cancer Center-BioSpecimen Center for their invaluable contributions to collecting samples. We thank Yoko Odaka, Suenori Chiku, Noriko Abe, Sachiko Miura, Chizu Kina, Tsuyuka Ohtsuki, Yuka Asami, Y. Yukawa, Y. Yokoyama, and technical staff at the Center for Genome Medicine. National Cancer Center (NCC), for providing technical/methodological assistance. This research was supported in part by the Japan Agency for Medical Research and Development (AMED) (JP15ck0106096 to TK), Japan Science and Technology Agency (JST) Core Research for Evolutionary Science and Technology (JPMJCR1689 to RH) and Artificial Intelligence, Big Data, IoT, Cyber Security Integration Project of the Public/Private R&D Investment Strategic Expansion Program (JPMJCR18Y4 to RH), the Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (S) (17H06162 to HN), Grant-in-Aid for Scientific Research (B) (20H03695 to KS), Grants-in-Aid for the Tailor-Made Medical Treatment Program (BioBank Japan Project) from the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT), Princess Takamatsu Cancer Research Fund, and National Cancer Center Research and Development Fund (NCC Biobank and NCC Core Facility). The J-MICC study was supported by Grants-in-Aid for Scientific Research for Priority Areas of Cancer (No. 17015018 to KW) and Innovative Areas (No. 221S0001 to KW) from MEXT, and by JSPS Grant-in-Aid for Scientific Research Grant (No. 16H06277 [CoBiA]). The JPHC Study was supported by National Cancer Center Research and Development Fund since 2011 (latest grant number: 2020-J4) and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare of Japan (1989-2010). ToMMo is supported in part by MEXT-JST and AMED (most recent grant numbers: JP20km0105001 and JP20km0105002). Iwate Tohoku Medical Megabank Organization (Iwate Medical University) is supported in part by MEXT-JST and AMED (most recent grant numbers: JP20km0105003 and JP20km0105004).

CONFLICT OF INTEREST STATEMENT The authors declare no competing interests.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

All participating studies obtained informed consent from the participants by following the protocols approved by their institutional ethical committees. The present study was approved by the ethical committees of each participating institution (ethics approval numbers: 2005-109, 2013-060, 2015-159, 2015-278, 2011-044).

CONSENT FOR PUBLICATION Not applicable.

DATA AVAILABILITY STATEMENT

Genome data are available from the National Bioscience Database Center (NBDC) Human Database (research ID: hum0014 and hum0012.v1). Summary GWAS1 and GWAS2 data can be freely downloaded from https://epi.ncc.go.jp/ cgi-bin/cms/public/index.cgi/jcge/en/download/index.

> Kouva Shiraishi^{1,2} Atsushi Takahashi^{3,4} Yukihide Momozawa⁵ Yataro Daigo^{6,7} Syuzo Kaneko⁸ Takahisa Kawaguchi⁹ Hideo Kunitoh¹⁰ Shingo Matsumoto¹¹ Hidehito Horinouchi¹² Akiteru Goto¹³ Takayuki Honda¹⁴ Kimihiro Shimizu^{15,16} Masahiro Torasawa^{1,12} Daisuke Takayanagi¹ 🕩 Motonobu Saito¹⁷ Akira Saito¹⁸ Yuichiro Ohe¹² Shun-ichi Watanabe¹⁹ Koichi Goto¹¹ Masahiro Tsuboi²⁰ Katsuya Tsuchihara²¹ Sadaaki Takata⁵ 🕩 Tomomi Aoi⁵ Atsushi Takano⁶ Masashi Kobayashi²² Yohei Miyagi²³ Kazumi Tanaka¹⁶ Hirovuki Suzuki²⁴ Daichi Maeda¹³ Takumi Yamaura²⁴ Maiko Matsuda¹ Yoko Shimada¹ Takaaki Mizuno^{1,12} Hiromi Sakamoto²⁵ Teruhiko Yoshida²⁶ Yasushi Goto¹² Tatsuya Yoshida¹² Taiki Yamaji²⁷ Makoto Sonobe²⁸ Shinichi Toyooka²⁹ Kazue Yoneda³⁰ Katsuhiro Masago³¹ Fumihiro Tanaka³⁰ Megumi Hara³² Nobuo Fuse³³ Satoshi S. Nishizuka³⁴

291

⁶Center for Antibody and Vaccine Therapy, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan ⁷Department of Medical Oncology and Cancer Center, and Center for Advanced Medicine against Cancer, Shiga University of Medical Science, Otsu, Japan ⁸Division of Medical AI Research and Development. National Cancer Center Research Institute, Tokyo, Japan ⁹Center for Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan ¹⁰Department of Medical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan ¹¹Department of Thoracic Oncology, National Cancer Center Hospital East. Japan ¹²Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan ¹³Department of Cellular and Organ Pathology, Graduate School of Medicine. Akita University. Akita. Japan ¹⁴Department of Respiratory Medicine, Tokyo Medical and Dental University, Bunkvo-ku, Tokvo, Japan ¹⁵Division of General Thoracic Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan ¹⁶Department of General Surgical Science, Division of General Thoracic Surgery, Gunma University Graduate School of Medicine, Integrative Center of General Surgery, Gunma University Hospital, Gunma, Japan ¹⁷Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan ¹⁸StaGen Co., Ltd, Tokyo, Japan ¹⁹Division of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan ²⁰Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan ²¹Division of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Chiba, Japan ²²Department of Thoracic Surgery, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan ²³Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Kanagawa, Japan ²⁴Department of Chest Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan ²⁵Fundamental Innovative Oncology Core Center, National Cancer Center Research Institute, Tokvo, Japan ²⁶Department of Genetic Medicine and Services, National Cancer Center Hospital, Tokyo, Japan ²⁷Division of Epidemiology, National Cancer Center Institute for Cancer Control, Tokyo, Japan ²⁸Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan

Noriko Motoi³⁵ Norie Sawada²⁷ Yuichiro Nishida³² 🕩 Kazuki Kumada³³ Kenji Takeuchi³⁶ Kozo Tanno³⁴ Yasushi Yatabe³⁵ Kuniko Sunami¹ Tomoyuki Hishida^{20,37} Yasunari Miyazaki¹⁴ Hidemi Ito³⁸ Mitsuhiro Amemiya¹⁸ Hirohiko Totsuka¹⁸ Haruhiko Nakavama³⁹ Tomoyuki Yokose⁴⁰ Kazuvoshi Ishigaki³ Toshiteru Nagashima¹⁶ Yoichi Ohtaki¹⁶ Kazuhiro Imai⁴¹ Ken Takasawa⁸ Yoshihiro Minamiya⁴¹ Kazuma Kobayashi⁸ Kenichi Okubo²² Kenji Wakai³⁶ Atsushi Shimizu³⁴ Masayuki Yamamoto³³ Motoki Iwasaki^{27,42} Koichi Matsuda43 Johji Inazawa⁴⁴ Yuichi Shiraishi45 Hiroyoshi Nishikawa⁴⁶ Yoshinori Murakami⁴⁷ Michiaki Kubo⁵ Fumihiko Matsuda⁹ Yoichiro Kamatani³ Ryuji Hamamoto⁸ 💿 Keitaro Matsuo⁴⁸ Takashi Kohno¹ 💿

¹Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan
²Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan
³Laboratory for Statistical Analysis, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
⁴Department of Genomic Medicine, Research Institute, National Cerebral and Cardiovascular Center, Osaka, Japan
⁵Laboratory for Genotyping Development, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan

²⁹Departments of General Thoracic Surgery and Breast and Endocrinological Surgery, Okavama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan ³⁰Second Department of Surgery, University of Occupational and Environmental Health, Kitakvushu, Japan ³¹Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagova, Japan ³²Department of Preventive Medicine, Faculty of Medicine, Saga University, Saga, Japan ³³Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan ³⁴Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Iwate, Japan ³⁵Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan ³⁶Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan ³⁷Division of Thoracic Surgery, Department of Surgery, Keio University School of Medicine, Tokyo, Japan ³⁸Division of Cancer Information and Control, Aichi Cancer Center Research Institute, Nagoya, Japan ³⁹Department of Thoracic Surgery, Kanagawa Cancer Center, Kanagawa, Japan ⁴⁰Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan ⁴¹Department of Thoracic Surgery, Graduate School of Medicine, Akita University, Akita, Japan ⁴²Division of Cohort Research, National Cancer Center Institute for Cancer Control, Tokvo, Japan ⁴³Laboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Science, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan ⁴⁴Department of Molecular Cytogenetics, Medical Research Institute and Bioresource Research Center, Tokyo Medical and Dental University, Tokyo, Japan ⁴⁵Division of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan ⁴⁶Division of Cancer Immunology, Research Institute, National Cancer Center, Tokyo, Japan ⁴⁷Division of Molecular Pathology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan ⁴⁸Division of Molecular and Clinical Epidemiology, Aichi Cancer Center Research Institute, Nagoya, Japan

Correspondence

Takashi Kohno and Kouya Shiraishi, Division of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. Email: tkkohno@ncc.go.jp and kshirais@ncc.go.jp Keitaro Matsuo, Division of Molecular and Clinical Epidemiology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan. Email: kmatsuo@aichi-cc.jp

Ryuji Hamamoto, Division of Medical AI Research and Development, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. Email: rhamamot@ncc.go.jp

Yoichiro Kamatani, Laboratory for Statistical Analysis, Center for Integrative Medical Sciences, RIKEN, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan.

Email: yoichiro.kamatani@riken.jp

Fumihiko Matsuda, Center for Genomic Medicine, Graduate School of Medicine, Kyoto University, Yoshida-honmachi, Sakyo-ku, Kyoto-shi, 606-8501, Japan. Email: fumi@genome.med.kyoto-u.ac.jp

ORCID

Kouya Shiraishi Dhttps://orcid.org/0000-0002-5821-7400 Daisuke Takayanagi Dhttps://orcid.org/0000-0001-9644-9782

Sadaaki Takata https://orcid.org/0000-0002-5354-5341 Yuichiro Nishida https://orcid.org/0000-0003-2320-7234

Ryuji Hamamoto https://orcid.org/0000-0002-2632-1334

Takashi Kohno D https://orcid.org/0000-0002-5371-706X

REFERENCES

- 1. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers–a different disease. Nat Rev Cancer 2007;7(10):778–90.
- 2. Shiraishi K, Okada Y, Takahashi A, Kamatani Y, Momozawa Y, Ashikawa K, et al. Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinoma. Nat Commun 2016;7:12451.
- 3. McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nat Genet 2017;49(7):1126–32.
- 4. Shi J, Shiraishi K, Choi J, Matsuo K, Chen TY, Dai J, et al. Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population. Nat Commun 2023;14(1):3043.
- Byun J, Han Y, Li Y, Xia J, Long E, Choi J, et al. Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. Nat Genet 2022;54(8):1167–77.
- Blackburn EH, Epel ES, Lin J. Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection. Science 2015;350(6265):1193–98.
- DeBoy EA, Tassia MG, Schratz KE, Yan SM, Cosner ZL, McNally EJ, et al. Familial Clonal Hematopoiesis in a Long Telomere Syndrome. N Engl J Med 2023;388(26):2422–33.

293

8. Markozannes G, Kanellopoulou A, Dimopoulou O, Kosmidis D, Zhang X, Wang L, et al. Systematic review of Mendelian randomization studies on risk of cancer. BMC Med 2022; 20(1):41.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.